Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?

Table 2 Median adherence percentage with inter-quartile range at each study visit, by adherence measure

	n	Week 16	n	Week 48
Self-report (%): median (IQR)	140	100 (100–100)	169	100 (100–100)
Pill count (%): median (IQR)	160	100 (92–100)	178	100 (95–107)
Average pharmacy refill (%): median (IQR)^a	158	104 (101–105)	178	103 (95–105)
Gaps pharmacy refill (%): median(IQR)^a	158	100 (100–100)	178	100 (95–100)
EAMD adherence (%): median (IQR)^a	160	93 (74–98)	180	86 (59–94)
EFV concentration (mg/L): median(IQR)	136	2.3 (1.6–4.4)	156	2.1 (1.5–3.4)
Viral suppression: n (%)	160	146 (91.2)	180	153 (85.0)

Self-report and EFV concentrations are measured on the date of the visit. Tablet counts cover the 30 days (week 16) or 60 days (week 48) before the visit. Pharmacy refill and EAMD adherence are cumulative data from baseline to latest time in care
^aCumulative per protocol measures

ISSN: 1742-6405